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Conclusions: NGF plasma levels did not differ in patients and controls. 
In our cohort with advanced NSCLC we have not found any relation-
ship between NGF levels with histology, response, site of metastasis 
and TTP. By contrast NGF levels are higher in those patients in stage 
IV and in those presenting poorer OS.
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Background: Cyckooxygenase 2 (Cox-2) plays a key role in progres-
sion and survival of non-small cell lung cancer (NSCLC) through 
regulation of apoptosis, angiogenesis, invasion and metastasis. We have 
previously shown that carriers of a common polymorphism in the 3`-
UTR of the Cox-2 gene have increased risk of NSCLC. 
Methods: This study comprises 257 Norwegian patients treated by 
surgery for early stage NSCLC, from 1988 to end 2003. We analysed 
lung cancer speciﬁc survival by end 2004, related to the polymorphic 
genotypes of the Cox-2 gene, tumour histology, tumour Cox-2 protein 
expression detected by immunohistochemistry, and the mutational 
status of the p53 gene. The Cox-2 3`-UTR SNP (SNP database rs5275) 
was genotyped in DNA from blood samples using the Taqman meth-
odology, p53 mutations (exons 4 - 9) were analysed in tumour DNA by 
sequencing. We used Cox-2 (CloneSP21) rabbit monoclonal antibody 
and Ultra Vision Detection system (Lab Vision) for immunostaining. 
Survival curves were assessed by Kaplan-Meier univariate analysis and 
further by Cox multiple regression analysis.
Results: The mean age was 64,2 yrs, ranging from 25 to 84 yrs, 
71%were males and 29% females. Histologically 103 (40%) were 
squamous cell carcinomas, 108 (42%) adenocarcinomas and 46 (18%) 
were large cell carcinomas. The frequency of Cox-2 genotypes was C/C 
(15,6%), CT (41,6%), T/T (42,8%). Mean survival time was reduced in 
all patients harbouring the C-allele, compared to those with the T-allele 
(survival time 3,3yrs versus 7,9yrs) (P=0,01). The C-allele was con-
ﬁrmed as a risk allele for reduced survival notably in adenocarcinoma 
(P=0,031), Lung cancer speciﬁc survival for patients with the C/C 
genotype remained poorer after adjusting for age, gender, and smoking 
in the multivariate analysis. 
In a subset of 216 patients 126 (58%) had p53 gene mutations in the 
tumours. In the remaining patients without p53 mutations (42%), the 
C-allele was clearly associated with poor survival compared to the T-al-
lele (P=0,006).
We observed slight increase in survival among patients with positive 
Cox-2 immunostaining, compared to those without positive staining. 
Patients harbouring both the C-allele and presenting positive immu-
nostaining lived slightly shorter than those with C-allele, but without 
positive immunostaining (2,6 versus 3,1 yrs), although not statistically 
signiﬁcant. We are currently studying the functional role of this SNP.
Conclusion: In patients with NSCLC the variant Cox-2 genotype 
C/C confers poor prognosis, notably in patients with adenocarcinoma. 
Patients with a wild-type p53 gene, and also harbouring the Cox-2 vari-
ant genotype C/C live shorter compared to those patients with the T/T 
genotype.
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Background: C4.4A is implied in human cancer progression. This 
glycolipid-anchoed protein is a structural homologue of the urokinase 
receptor, uPAR, which is a well-established prognostic marker in vari-
ous human cancers. Although, several pilot studies recognises C4.4A 
expression in various human tumors little is known about its prognos-
tic signiﬁcance. We therefore aim to explore the possible association 
between C4.4A expression and clinicopathological features and disease 
prognosis in patients with non-small cell lung cancer (NSCLC).
Methods: Tissue sections from 109 NSCLC patients were subjected to 
immunohistochemical staining using a polyclonal antibody that speciﬁ-
cally recognizes human C4.4A. Staining frequency and intensity was 
scored semiquantitatively and grouped into cancers with high and low 
expression of C4.4A. Kaplan-Meier survival curves were generated to 
evaluate the signiﬁcance of C4.4A expression in prognosis of NSCLC 
patients. 
Results: High C4.4A expression was observed in 44% of the speci-
mens analyzed, and it correlates with overall survival (P=0.012). 
Intriguingly, a very strong correlation was noted between high expres-
sion of C4.4A in pulmonary adenocarcinoma and survival (P<0.0001). 
Multivariate Cox regression analysis shows that high C4.4A expression 
is an independent predictor of poor disease outcome in NSCLC (risk 
ratio, 1.42; 95% conﬁdence interval, 1.09-1.86; P=0.009). Although, 
histological type is not a predictor of outcome in NSCLC, high C4.4A 
expression in adenocarcinoma is nevertheless a very strong predictor of 
poor disease outcome (risk ratio, 1.62; 95% conﬁdence interval, 1.24-
2.09; P=0.001).
Conclusions: High C4.4A expression in tumor cell is associated with 
shorter survival for NSCLC patients. Patients with pulmonary adeno-
carcinoma have a particularly poor prognosis if this histological type is 
combined with high C4.4A expression. 
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Background: Nearly half of early stage SqCLC patients (pts) will 
relapse after surgery, with distant metastasis being the main cause of 
